Research programme: iPSCs-derived CAR NK therapies - Cytovia Therapeutics/New York Stem Cell Foundation
Alternative Names: GPC3 CAR NK cell therapies; Induced pluripotent stem cells-derived chimeric antigen receptor natural killer cell therapies - Cytovia Therapeutics/The New York Stem Cell Foundation; Research programme: iPSCs-derived CAR NK therapies - Cytovia Therapeutics/The New York Stem Cell FoundationLatest Information Update: 28 Nov 2024
At a glance
- Originator Cytovia Therapeutics; The New York Stem Cell Foundation
- Class CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 05 Oct 2020 Preclinical trials in Cancer in USA (Parenteral) before October 2020 (Cytovia Therapeutics pipeline, October 2020)
- 25 Aug 2020 Cytovia Therapeutics and the New York Stem Cell Foundation Research institute plans to file patents on the engineering, expansion and Good Manufacturing Practices manufacturing processes of induced pluripotent stem cells natural killer cells to treat cancer